Oregon Health and Science University and Portland VA Medical Center, Portland, OR 97239, USA.
J Alzheimers Dis. 2013;33 Suppl 1(Suppl 1):S371-6. doi: 10.3233/JAD-2012-129022.
The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a "presymptomatic" stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine "go- no go" decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.
阿尔茨海默病的惰性特征，加上人们对疾病“前临床阶段”日益增长的兴趣，促使人们努力识别、验证和利用替代疾病标志物，以进行疾病修饰或预防策略的试验。这些努力中有许多是富有成效的，生物标志物现在已被常规用于研究对象的选择和临床试验结果的评估。另一方面，生物标志物也有可能在早期药物开发中决定“前进或停止”决策时导致不良的治疗结果。本文综述了几项生物标志物研究报告，这些报告说明了阿尔茨海默病生物标志物具有巨大的潜力，既有好的方面，也有坏的方面。
